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Dear Editor,
Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive 
AML accounts for <1% of newly diagnosed AML cases [1]. Al-
though the role of Ph in CML pathogenesis has been elucidated, 
Ph+ AML pathogenesis remains controversial. Ph+ AML is be-
lieved to represent the de novo myeloid blast phase (BP) of 
CML and, therefore, was not recognized in the 2008 WHO clas-
sification of myeloid neoplasms and acute leukemia [2].
Konoplev et al. [3] presented molecular evidence suggesting 
that Ph+ AML is a clinicopathological entity distinct from CML-
BP, in a study involving nine patients with Ph+ AML and five pa-
tients with CML-BP at their initial presentations. They showed 
that patients with Ph+ AML carried the nucleophosmin (NPM1) 
mutation at a similar frequency as that seen in all cases of AML, 
and that they lacked ABL1 mutations that occur in a proportion 
of patients with CML-BP. Internal tandem duplication (ITD) of 
the Fms-like receptor tyrosine kinase 3 (FLT3) was detected in 
a Ph+ AML patient, but no Ph+ AML patients harbored both the 
NPM1 mutation and the FLT3 ITD. We present a rare case of 
BCR-ABL1-positive AML with both the NPM1 mutation and the 
FLT3 ITD.
A 79-yr-old woman was referred to our hospital after several 
months of general weakness and weight loss. She had under-
gone surgery for acute appendicitis one year earlier. Her initial 
white blood cell count was 157.5×109/L (80% blasts and 1% 
basophils), hemoglobin was 11.8 g/dL, and platelet count was 
87×109/L. She did not show organomegaly or lymphadenopa-
thy. Her bone marrow (BM) was packed with blasts (92.3% of 
all nucleated cells) with cup-like nuclear indentation (Fig. 1) 
and showed no significant dyshematopoietic features. Flow cy-
tometry revealed that the blasts were positive for CD13 (94%), 
CD33 (98%), CD34 (72%), HLA-DR (46%), and cytoplasmic 
myeloperoxidase (86%). Chromosome analysis revealed t(2;5)
(p12;p15) in 20 metaphases, which was considered a constitu-
tional chromosomal abnormality. Multiplex reverse transcription 
(RT)-PCR using HemaVision kit (DNA Diagnostic A/S, Risskov, 
Denmark) revealed the presence of minor BCR-ABL1 (e1a2) fu-
sion transcripts. Interphase FISH analysis of formalin-fixed par-
affin-embedded tissue from BM trephine biopsy section showed 
no fusion signals by using locus specific identifier BCR/ABL 
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dual-color, dual-fusion translocation probe set (Abbott Molecu-
lar/Vysis, Des Plaines, IL, USA).
Genomic DNA was amplified to detect the FLT3 ITD and 
NPM1 exon 12 mutations. Total RNA was extracted and RT-
PCR was carried out to amplify the BCR/ABL kinase domain. 
Direct sequencing of the amplified products revealed that our 
Fig. 1. Bone marrow findings of the patient. (A) Aspirate smear showing increased blasts (Wright-Giemsa, ×1,000). The blasts with cup-
like nuclei and fish mouth nuclei (inlet) are observed. (B) Biopsy section showing a diffuse infiltration by the blasts (Hematoxylin and eosin, 
×200). 
Fig. 2. Sequencing analyses show the presence of type A mutation (c.863_864insTCTG) in the nucleophosmin gene (NPM1) (A) and an 
FLT3 internal tandem duplication (ITD) with a 45 bp in-frame duplication (c.1788_1832dup) (B). Arrows indicate the insertion sites.
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patient had type A mutations of NPM1 (Fig. 2A) and FLT3 ITD 
(Fig. 2B), but no ABL1 mutations.
The patient was diagnosed as having AML without matura-
tion, according to the 2008 WHO classification of haematopoi-
etic and lymphoid tumors [4], and was considered to have a 
cryptic e1a2 BCR-ABL1 fusion. Although cytarabine and 
decitabine therapy was started, the patient died one week after 
AML diagnosis.
The clinicopathological features that suggested Ph+ AML 
rather than CML-BP included the absence of a clinical history of 
hematologic disorders (including CML and MDS); no dwarf 
megakaryocytes, splenomegaly, or basophilia; and the absence 
of an extra Ph, trisomy 8, trisomy 19, or isochromosome 17q [3, 
5]. This case showed clinical and laboratory features compatible 
with Ph+ AML, as mentioned above.
Considering the findings of Konoplev’s cases [3] and this case, 
NPM1 mutations and FLT3 ITD may be concurrent genetic ab-
normalities in patients with Ph+ AML. The coexistence of the 
FLT3 ITD and the NPM1 mutations, as observed in our patient, 
is reported in about 40% of patients with AML and mutated 
NPM1 [6]. This case supports the idea that Ph+ AML is a dis-
tinct entity. Another study also showed that NPM1 mutations oc-
cur only in patients with AML and not in those with CML, 
whereas ABL1 mutations are common in patients with CML [7]. 
Furthermore, a high-resolution array-based comparative ge-
nomic hybridization study indicated that a unique loss within im-
munoglobulin genes provides a simple test to differentiate clini-
cally similar de novo Ph+ AML cases from CML-BP cases [1].
To our knowledge, our patient is the first case of Ph+ AML 
with both FLT3 ITD and NPM1 mutations. Ph+ AML cases 
seem to have different molecular or genomic features from 
those with CML-BP [1, 3, 8]. However, to describe Ph+ AML as 
a discrete entity in the WHO classification, it is important to doc-
ument more cases and perform more aggressive diagnostic 
workups, including FLT3 ITD and NPM1 mutational analyses 
and analysis of immunoglobulin genes. Especially, a hemato-
pathologist should keep in mind that cup-like nuclei and fish 
mouth nuclei may represent an important morphologic clue to 
provoke testing for both the FLT3 ITD and the NPM1 mutations 
[9, 10].
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